Can There Be International Agreement on How to Navigate the Future of Genome Editing?

April 5th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Our world is changing at an astonishingly rapid pace and, as described a few weeks ago, CRISPR is poised to become a major source of change in many fields, from medicine to animals to crops. With any new technology, but especially one that has ...

10 Years of CRISPR – Developing a Previously Unimaginable Idea to Benefit the World

March 15th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

CRISPR is now a common term, one that you see even in mainstream media. Yet it is incredible to think that its potential for editing genes was published just ten years ago. In a mere decade, the groundbreaking discovery has been successfully developed to ...

The Journey of C. Frank Bennett: Caring and Curiosity Drive the Development of Antisense Therapies

March 2nd, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

The chief scientific officer of Ionis Pharmaceuticals, Dr. C. Frank Bennett, is not someone who comes to work just to do science, but to help his patients. Although he started with little knowledge of antisense drugs when he joined the company more than thirty ...

RSV: Developing Vaccines to Protect the Vulnerable

February 13th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

It’s the middle of winter and, at some point during this season, many people will experience a constellation of symptoms that may include coughing, a sore throat, runny nose, headache, body aches, fevers, and fatigue. Most adults would assume they have a cold or ...

Inclisiran’s Interesting Path to Treating LDL Cholesterol

January 31st, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

When The Medicines Company licensed inclisiran, they envisioned a drug for the masses that would save the healthcare system money and be reasonably priced for patients. Despite the company having little experience in the oligonucleotide therapeutics field, it went all in on the drug, selling ...

Alnylam’s 20-Year Journey of Discovery

January 19th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Twenty years ago, a group of scientists intent on developing a new class of medicine using RNAi technology came together and formed Alnylam Pharmaceuticals, a name symbolizing their passion for discovery. The bright center star of Orion's belt, Alnilam, has long been used as a ...

New CRISPR Technique May Be the Solution to Replacing Entire Genes

January 4th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Ever since it was discovered that CRISPR could be used for genome editing, scientists across the world have been working on creating safe, effective ways to use this incredible tool to cure many different human diseases. From the first CRISPR-Cas system that works as ...

Using CRISPR to Personalize Cancer Immunotherapy Treatment

December 12th, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

In 2020, there were an estimated 18.1 million cases of cancer worldwide (excluding non-melanoma skin cancer). Breast, lung, and colorectal cancer were the most common and together contributed to 35.4% of these cases. In the same year, 9.5 million cancer-related deaths were reported. According to ...

Will N-of-1 Drugs Play a Role in the Future of Medicine?

November 22nd, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Throughout the millennia, anyone who had anything beyond a simple illness could only do their best to ease the pain and petition whatever deities their culture believed in. Then, in the past few centuries, medicine and science have advanced to the point that many ...

Centyrins Effectively and Safely Deliver siRNAs to Multiple Muscle Tissues

November 9th, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

In 2018, Susan Dillon and Karyn O'Neil knew they had created something special that could change the treatment of genetic diseases. Now, their company’s drug that uses their proprietary technology has been granted orphan drug status by the U.S Food and Drug Administration (FDA). ...

Go to Top